BioPharmaceutical Business Intelligence

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
McKesson
Merck
Chinese Patent Office
Fuji
QuintilesIMS
Boehringer Ingelheim
Deloitte
Accenture
Johnson and Johnson

Generated: January 19, 2018

DrugPatentWatch Database Preview

Terbinafine - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for terbinafine and what is the scope of terbinafine patent protection?

Terbinafine
is the generic ingredient in three branded drugs marketed by Glaxosmithkline Cons, Novartis, Glaxosmithkline, Taro, Apotex, Aurobindo Pharma, Breckenridge Pharm, Cipla Ltd, Dr Reddys Labs Inc, Gedeon Richter Usa, Glenmark Generics, Harris Pharm, Invagen Pharms, Mylan, Orchid Hlthcare, Roxane, Teva, and Wockhardt, and is included in twenty-four NDAs. Additional information is available in the individual branded drug profile pages.

There are twenty-six drug master file entries for terbinafine. One supplier is listed for this compound. There are four tentative approvals for this compound.
Tentative approvals for TERBINAFINE
Applicant Application No. Strength Dosage Form
➤ Subscribe➤ SubscribeEQ 250MG BASETABLET; ORAL
➤ Subscribe➤ SubscribeEQ 250MG BASETABLET;ORAL
➤ Subscribe➤ SubscribeEQ 250MG BASETABLET;ORAL

US Patents and Regulatory Information for terbinafine

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Mylan TERBINAFINE HYDROCHLORIDE terbinafine hydrochloride TABLET;ORAL 077195-001 Jul 2, 2007 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Wockhardt TERBINAFINE HYDROCHLORIDE terbinafine hydrochloride TABLET;ORAL 078229-001 Jul 2, 2007 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Aurobindo Pharma TERBINAFINE HYDROCHLORIDE terbinafine hydrochloride TABLET;ORAL 078297-001 Jul 2, 2007 AB RX No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Novartis LAMISIL terbinafine hydrochloride CREAM;TOPICAL 020192-001 Dec 30, 1992 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Novartis LAMISIL AT terbinafine GEL;TOPICAL 021958-001 Jul 24, 2006 OTC Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Novartis LAMISIL terbinafine hydrochloride GRANULE;ORAL 022071-001 Sep 28, 2007 DISCN Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Breckenridge Pharm TERBINAFINE HYDROCHLORIDE terbinafine hydrochloride TABLET;ORAL 077714-001 Jun 4, 2010 AB RX No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Taro TERBINAFINE HYDROCHLORIDE terbinafine hydrochloride CREAM;TOPICAL 077511-001 Jul 2, 2007 OTC No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Glaxosmithkline Cons LAMISIL terbinafine hydrochloride SOLUTION;TOPICAL 020749-001 Oct 17, 1997 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Mylan TERBINAFINE HYDROCHLORIDE terbinafine hydrochloride TABLET;ORAL 077136-001 Jul 2, 2007 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for terbinafine

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Glaxosmithkline Cons LAMISIL terbinafine GEL;TOPICAL 020846-001 Apr 29, 1998 ➤ Subscribe ➤ Subscribe
Glaxosmithkline Cons LAMISIL terbinafine GEL;TOPICAL 020846-001 Apr 29, 1998 ➤ Subscribe ➤ Subscribe
Novartis LAMISIL AT terbinafine GEL;TOPICAL 021958-001 Jul 24, 2006 ➤ Subscribe ➤ Subscribe
Glaxosmithkline Cons LAMISIL terbinafine GEL;TOPICAL 020846-001 Apr 29, 1998 ➤ Subscribe ➤ Subscribe
Glaxosmithkline Cons LAMISIL terbinafine GEL;TOPICAL 020846-001 Apr 29, 1998 ➤ Subscribe ➤ Subscribe
Glaxosmithkline Cons LAMISIL terbinafine GEL;TOPICAL 020846-001 Apr 29, 1998 ➤ Subscribe ➤ Subscribe
Glaxosmithkline Cons LAMISIL terbinafine GEL;TOPICAL 020846-001 Apr 29, 1998 ➤ Subscribe ➤ Subscribe
Novartis LAMISIL AT terbinafine GEL;TOPICAL 021958-001 Jul 24, 2006 ➤ Subscribe ➤ Subscribe
Novartis LAMISIL AT terbinafine GEL;TOPICAL 021958-001 Jul 24, 2006 ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Dow
Citi
Chinese Patent Office
Queensland Health
Moodys
US Department of Justice
McKesson
Farmers Insurance
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot